Finally, it has been reported most recently that blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleashed the immune responses in combination cancer therapies using immune checkpoint inhibitors and chemotherapies [18]. This evidence concerns the gene NT5E and cancer.